《大行報告》大摩上調三生製藥(01530.HK)目標價至7.5元 評級「與大市同步」
摩根士丹利發表報告指,由於在疫情下內地藥品集中採購實施日期進一步推遲等,預期三生製藥(01530.HK)今年的銷售增長目標會由10%以下,調升至雙位數;至於盈利因匯兌收益影響,估計會增長20%至30%。
集團管理層指引明年收入及盈利增長逾10%,該行認為考慮到宏觀的不確定性、監管環境不斷變化及今年的利潤基礎高,相信指引需謹慎執行。
大摩上調三生製藥股份目標價,由6.2元升至7.5元,評級維持「與大市同步」,並調升集團今年至2024年銷售預測分別5%、6%及7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.